



australasian society of clinical immunology and allergy

13 January 2022

Professor Andrew Wilson,  
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)  
Department of Health and Ageing  
GPO Box 9848 Canberra ACT 2601  
Email: [pbac@health.gov.au](mailto:pbac@health.gov.au)

Dear Professor Wilson,

**Re: Dupixent® (dupilumab) for treatment of severe atopic dermatitis in children aged 6-11 years**

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA) I am writing in support of an application from Sanofi-Aventis Australia Pty Ltd for Dupixent® (dupilumab) to be listed on the Pharmaceutical Benefits Scheme (PBS) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years,

ASCIA strongly supports this application for the following reasons:

- The PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis in patients aged 12 years or more, has made a significant difference to the health-related quality of life for these patients, which can greatly assist with learning outcomes and increased productivity.
- Prior to the PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis in patients aged 12 years or more, if patients failed to achieve a good response to topical eczema management, the only option is to consider was immunosuppressive treatments, all of which have weak evidence base, considerable possible side effects, long term effects and need for frequent monitoring including blood tests.
- The PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis in children aged 6-11 years will make a significant difference to the health-related quality of life for these patients. This can greatly assist with learning outcomes and ensures equitable access to Australians of all age groups, who live with severe atopic dermatitis.

Clinical immunology/allergy specialists regularly manage patients of all ages with severe atopic dermatitis, and are experienced in appropriate selection and monitoring of these patients who are being treated using immune modulating agents, including Dupixent® (dupilumab).

We hope that this letter provides sufficient information for the proposed PBS listing of Dupixent® (dupilumab) in children aged 6-11 years, to be considered at the March 2022 PBAC meeting.

Yours sincerely,

Prof Michaela Lucas MD FRACP FRCPA  
ASCIA President